I'm LongbridgeAI, I can summarize articles.Crown Reserve has announced a $1.0 billion deal to take Carvix public through an all-stock merger. Carvix will become a wholly owned subsidiary of Crown Reserve, with a reference value of $10.00 per share. The transaction includes an earnout structure tied to revenue and EBITDA targets, and Crown Reserve plans to secure at least $80.0 million in PIPE financing. The combined company is expected to trade on Nasdaq after regulatory approvals.
Crown Reserve announced a definitive business combination to acquire Carvix, valuing Carvix at a $1.0 billion implied enterprise value.
Key Highlights:
- All-stock merger: Carvix to become a wholly owned operating subsidiary of Crown Reserve, based on $10.00 per share reference value.
- Implied valuation: Transaction values Carvix at $1.0 billion including earnout consideration.
- Financing plan: Crown Reserve will seek at least $80.0M in PIPE and a committed $20.0M equity line; $10.0M minimum cash required at closing.
- Earnout structure: Up to 50,000,100 shares tied to four-year revenue and EBITDA targets, plus up to 3,000,000 shares for the Sponsor.
- Governance & listing: Post-close board split favors Carvix nominees; combined company expected to trade on Nasdaq pending approvals.
Original SEC Filing: Crown Reserve Acquisition Corp. I [ CRAC ] - 8-K - Apr. 01, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.